SCHEMBL29655774

SCHEMBL29655774

O=C(NC1CC1)c1ccc2c(c1)C1(CCO2)CC1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
GAA P10253 1/20 0.52
KMT2A Q03164 1/20 0.51
MAPK11 Q15759 1/20 0.51
MAPK14 Q16539 1/20 0.51
TP53 P04637 1/20 0.50
HPGD P15428 1/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SMYD3 Q9H7B4 6/20 0.48
CNR2 P34972 1/20 0.47
CHRNA7 P36544 2/20 0.46
PTGER4 P35408 1/20 0.45
ACHE P22303 1/20 0.44
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29655717 0.95 NPC1 (0.61) NPC1RAB9AGAAKMT2AMAPK11
SCHEMBL31743230 0.94 NPC1 (0.53) NPC1RAB9AGAAKMT2AMAPK11
SCHEMBL29655732 0.88 NPC1 (0.62) NPC1RAB9AGAAKMT2AMAPK11
SCHEMBL29696137 0.82 CYP26A1 (0.47) NPC1RAB9AGAAKMT2AHPGD
SCHEMBL30353220 0.82 RARA (0.54) NPC1RAB9A
SCHEMBL28347731 0.82 RARA (0.54) NPC1RAB9A
SCHEMBL29655794 0.81 MAPK14 (0.45) RAB9AKMT2AMAPK11MAPK14HPGD
SCHEMBL29655815 0.79 SMN1; SMN2 (0.47) NPC1RAB9AGAAKMT2ASMN1; SMN2
SCHEMBL30353262 0.77 KDM4E (0.54) NPC1RAB9AHPGD
SCHEMBL30353267 0.77 NPC1 (0.58) NPC1RAB9AKMT2ACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022138793-A1 COMBINATION BETWEEN EP2 RECEPTOR ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR AND/OR EP4 RECEPTOR ANTAGONIST 小野薬品工業株式会社 2022-06-30 WO disclosed
WO-2022102731-A1 CANCER TREATMENT BY COMBINED USE OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR 小野薬品工業株式会社 2022-05-19 WO disclosed